This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary MCAM Therapeutic Antibody Development
Background of MCAM
The expression of MCAM is linked to the invasiveness and metastatic potential of companion animal tumors, particularly in melanoma. BioVenic offers veterinary MCAM therapeutic antibody development services. Our one-stop service encompasses necessary processes for antibody development, including antibody design, preparation, and functional validation, supplemented by antibody engineering services, to assist in developing high-quality, high-affinity, and safe veterinary therapeutic antibodies.
Background of MCAM
| Full Name | Melanoma cell adhesion molecule |
|---|---|
| Aliases | CD146, HEMCAM, MelCAM, METCAM, MUC18. |
| Target Profile | MCAM, a transmembrane glycoprotein belonging to the immunoglobulin superfamily, plays a crucial role in intercellular interactions and signal transduction. It is one of the numerous proteins forming the vascular endothelial junctions, expressed in various tissues, especially in different cells constituting the blood vessels; namely, endothelial cells, smooth muscle cells, and pericytes. Pathologically, MCAM is associated with the tumor thickness and metastatic potential of melanoma cells. |
MoA of MCAM
Angiogenesis is a complex physiological process that requires extensive signaling interactions between endothelial cells, related vascular wall cells (such as smooth muscle cells and pericytes), and other types of cells, including immune cells. As a key molecule, MCAM serves both as a co-receptor for VEGFR2 and PDGFR-β and as an independent receptor for growth factors like Wnt5a, Wnt1, Netrin-1, FGF4, and VEGF-C. The high expression of MCAM enhances pro-angiogenic signal transduction, promoting cell growth, proliferation, differentiation, and survival. This aspect is crucial in understanding the interactions between MCAM and its ligands and their impact on the invasive growth, proliferation, and migration mechanisms of cancer cells.
Fig.1 Schematic diagram of MCAM as a growth factor receptor or co-receptor for growth factors.1
Application in Veterinary Therapeutics
Under pathological conditions like inflammation and tumor development, MCAM expression is upregulated in relevant cells, such as in canine oral melanomas, and other types of canine skin tumors including squamous cell carcinoma, infundibular keratinizing acanthoma, hair follicle tumors, and trichoepitheliomas. In felines, MCAM is also predominantly expressed in most cases of feline squamous cell carcinoma. Thus, considering MCAM as a potential target for the treatment of these types of companion animal tumors, MCAM antibodies represent a novel targeted therapeutic approach with minimal side effects and no widespread impairment of immune function.
Veterinary MCAM Therapeutic Antibody Development Services
The overexpression of MCAM may be associated with the initial development or metastatic progression of most types of companion animal cancers, primarily melanomas. BioVenic offers development services for veterinary MCAM therapeutic antibodies. Our services include the design, preparation, purification, and characterization of veterinary therapeutic antibodies to ensure high safety and efficacy. We also provide species-specific antibody development services, focusing on the immunogenicity of antibody samples, striving to offer more effective treatment solutions for companion animals.
Please click the link below for more information about our veterinary MCAM therapeutic antibody development services.
Why Choose Us?
BioVenic has established a platform offering various technologies for the preparation of veterinary therapeutic antibodies, including hybridoma technology, single B cell, and phage display techniques.
Our antibody engineering services encompass, but are not limited to, affinity maturation and Fc engineering, aimed at enhancing the affinity and extending the half-life of veterinary therapeutic antibody samples.
We provide species-specific antibody development services to minimize risks associated with immunogenicity, enhancing the applicability and effectiveness of antibody samples in companion animals.
The high expression of MCAM is associated with disease progression and poor prognosis, especially in cancers like melanomas. As the potential target for companion animal tumor treatment, BioVenic offers veterinary MCAM therapeutic antibody development services, helping you explore the potential of veterinary MCAM therapeutic antibodies in treating companion animal cancers. If you have development needs, please contact us immediately!
References
- Wang, Zhaoqing, et al. "CD146, from a melanoma cell adhesion molecule to a signaling receptor." Signal transduction and targeted therapy 5.1 (2020): 148.
- Abou Asa, S. "Immunohistochemical expression of MCAM/CD146 in canine melanoma." Journal of comparative pathology 157.1 (2017): 27-33.
- Kummer, Stefan, et al. "Feline SCCs of the Head and Neck Display Partial Epithelial-Mesenchymal Transition and Harbor Stem Cell-like Cancer Cells." Pathogens 12.11 (2023): 1288.